Atovaquone-Proguanil
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Atovaquone-Proguanil is {{{aOrAn}}} {{{drugClass}}} that is FDA approved for the treatment of {{{indication}}}. Common adverse reactions include {{{adverseReactions}}}.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
There is limited information regarding Atovaquone-Proguanil FDA-Labeled Indications and Dosage (Adult) in the drug label.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Atovaquone-Proguanil in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Atovaquone-Proguanil in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Atovaquone-Proguanil FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Atovaquone-Proguanil in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Atovaquone-Proguanil in pediatric patients.
Contraindications
4.1 Hypersensitivity MALARONE is contraindicated in individuals with known hypersensitivity reactions (e.g., anaphylaxis, erythema multiforme or Stevens-Johnson syndrome, angioedema, vasculitis) to atovaquone or proguanil hydrochloride or any component of the formulation.
4.2 Severe Renal Impairment MALARONE is contraindicated for prophylaxis of P. falciparum malaria in patients with severe renal impairment (creatinine clearance <30 mL/min) because of pancytopenia in patients with severe renal impairment treated with proguanil [see Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].
Warnings
There is limited information regarding Atovaquone-Proguanil Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Because MALARONE contains atovaquone and proguanil hydrochloride, the type and severity of adverse reactions associated with each of the compounds may be expected. The lower prophylactic doses of MALARONE were better tolerated than the higher treatment doses.
Prophylaxis of P. falciparum Malaria: In 3 clinical trials (2 of which were placebo‑controlled) 381 adults (mean age 31 years) received MALARONE for the prophylaxis of malaria; the majority of adults were black (90%) and 79% were male. In a clinical trial for the prophylaxis of malaria, 125 pediatric patients (mean age 9 years) received MALARONE; all subjects were black and 52% were male. Adverse experiences reported in adults and pediatric patients, considered attributable to therapy, occurred in similar proportions of subjects receiving MALARONE or placebo in all studies. Prophylaxis with MALARONE was discontinued prematurely due to a treatment‑related adverse experience in 3 of 381 (0.8%) adults and 0 of 125 pediatric patients.
In a placebo‑controlled study of malaria prophylaxis with MALARONE involving 330 pediatric patients (aged 4 to 14 years) in Gabon, a malaria-endemic area, the safety profile of MALARONE was consistent with that observed in the earlier prophylactic studies in adults and pediatric patients. The most common treatment‑emergent adverse events with MALARONE were abdominal pain (13%), headache (13%), and cough (10%). Abdominal pain (13% vs. 8%) and vomiting (5% vs. 3%) were reported more often with MALARONE than with placebo. No patient withdrew from the study due to an adverse experience with MALARONE. No routine laboratory data were obtained during this study.
Non‑immune travelers visiting a malaria‑endemic area received MALARONE (n = 1,004) for prophylaxis of malaria in 2 active-controlled clinical trials. In one study (n = 493), the mean age of subjects was 33 years and 53% were male; 90% of subjects were white, 6% of subjects were black and the remaining were of other racial/ethnic groups. In the other study (n = 511), the mean age of subjects was 36 years and 51% were female; the majority of subjects (97%) were white. Adverse experiences occurred in a similar or lower proportion of subjects receiving MALARONE than an active comparator (Table 3). Fewer neuropsychiatric adverse experiences occurred in subjects who received MALARONE than mefloquine. Fewer gastrointestinal adverse experiences occurred in subjects receiving MALARONE than chloroquine/proguanil. Compared with active comparator drugs, subjects receiving MALARONE had fewer adverse experiences overall that were attributed to prophylactic therapy (Table 3). Prophylaxis with MALARONE was discontinued prematurely due to a treatment‑related adverse experience in 7 of 1,004 travelers.
Postmarketing Experience
In addition to adverse events reported from clinical trials, the following events have been identified during postmarketing use of MALARONE. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to MALARONE.
Blood and Lymphatic System Disorders: Neutropenia and anemia. Pancytopenia in patients with severe renal impairment treated with proguanil [see Contraindications (4.2)].
Immune System Disorders: Allergic reactions including anaphylaxis, angioedema, and urticaria, and vasculitis.
Nervous System Disorders: Seizures and psychotic events (such as hallucinations); however, a causal relationship has not been established.
Gastrointestinal Disorders: Stomatitis.
Hepatobiliary Disorders: Elevated liver laboratory tests, hepatitis, cholestasis; hepatic failure requiring transplant has been reported.
Skin and Subcutaneous Tissue Disorders: Photosensitivity, rash, erythema multiforme, and Stevens-Johnson syndrome.
Drug Interactions
There is limited information regarding Atovaquone-Proguanil Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Atovaquone-Proguanil in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Atovaquone-Proguanil in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Atovaquone-Proguanil during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Atovaquone-Proguanil in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Atovaquone-Proguanil in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Atovaquone-Proguanil in geriatric settings.
Gender
There is no FDA guidance on the use of Atovaquone-Proguanil with respect to specific gender populations.
Race
There is no FDA guidance on the use of Atovaquone-Proguanil with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Atovaquone-Proguanil in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Atovaquone-Proguanil in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Atovaquone-Proguanil in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Atovaquone-Proguanil in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Atovaquone-Proguanil Administration in the drug label.
Monitoring
There is limited information regarding Atovaquone-Proguanil Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Atovaquone-Proguanil and IV administrations.
Overdosage
There is limited information regarding Atovaquone-Proguanil overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Atovaquone-Proguanil Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Atovaquone-Proguanil Mechanism of Action in the drug label.
Structure
There is limited information regarding Atovaquone-Proguanil Structure in the drug label.
Pharmacodynamics
There is limited information regarding Atovaquone-Proguanil Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Atovaquone-Proguanil Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Atovaquone-Proguanil Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Atovaquone-Proguanil Clinical Studies in the drug label.
How Supplied
There is limited information regarding Atovaquone-Proguanil How Supplied in the drug label.
Storage
There is limited information regarding Atovaquone-Proguanil Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Atovaquone-Proguanil |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Atovaquone-Proguanil |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Atovaquone-Proguanil Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Atovaquone-Proguanil interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Atovaquone-Proguanil Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Atovaquone-Proguanil Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.